Literature DB >> 35836904

Analysis of alterations of serum inflammatory cytokines and fibrosis makers in patients with essential hypertension and left ventricular hypertrophy and the risk factors.

Xia Li1, Xiaofan Guo1, Ye Chang1, Naijin Zhang1, Yingxian Sun1.   

Abstract

OBJECTIVE: This study mainly analyzed the alterations of serum inflammatory cytokines (ICs) and fibrosis makers in patients with essential hypertension (EH) and the risk factors (RFs).
METHODS: In this retrospective study, a total of 145 patients with EH admitted from January 2013 to January 2018 were selected as the research subjects, among which 89 patients without left ventricular hypertrophy (LVH) were included in the EH group and 56 patients with LVH were set as the LVH group. In addition, another 50 healthy subjects who underwent physical examination during the same period were selected as the healthy control (HC) group. The alterations of serum ICs such as interleukin (IL)-6, IL-10 and IL-18, and fibrosis makers like type III procollagen (PCIII), fibronectin (LN) and hyaluronic acid (HA) of the three groups were analyzed, and the RFs of LVH in EH patients were analyzed using the multivariate logistic model.
RESULTS: Statistically higher levels of IL-6, IL-18, PCIII, LN and HA with lower IL-10 levels were determined in the LVH group compared with the EH group. In comparison with the HC group, IL-6, IL-18, PCIII, LN and HA in the EH group were significantly higher, while IL-10 was significantly lower. On the other hand, BMI, LVMI, IL-6, IL-18, PCIII, LN, and HA were identified by multivariate logistic analysis to be the RFs affecting LVH in EH patients, while IL-10 was its protective factor.
CONCLUSIONS: The above results suggest that serum ICs (except IL-10) and fibrosis markers are up-regulated abnormally in EH patients with LVH, and BMI, LVMI, IL-6, IL-10, IL-18, PCIII, LN, and HA are all independent predictors of LVH in EH patients. AJTR
Copyright © 2022.

Entities:  

Keywords:  Hypertension; fibrosis; inflammatory cytokines; risk factors

Year:  2022        PMID: 35836904      PMCID: PMC9274558     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   3.940


  32 in total

1.  Quantification of doxorubicin-induced interstitial myocardial fibrosis in a beagle model using equilibrium contrast-enhanced computed tomography: A comparative study with cardiac magnetic resonance T1-mapping.

Authors:  Zhen Zhou; Lei Xu; Rui Wang; Akos Varga-Szemes; James A Durden; U Joseph Schoepf; Zhonghua Sun; Zhanming Fan
Journal:  Int J Cardiol       Date:  2019-01-15       Impact factor: 4.164

Review 2.  Prevalence of left-ventricular hypertrophy in hypertension: an updated review of echocardiographic studies.

Authors:  C Cuspidi; C Sala; F Negri; G Mancia; A Morganti
Journal:  J Hum Hypertens       Date:  2011-11-24       Impact factor: 3.012

Review 3.  Inflammation in Hypertension.

Authors:  Liang Xiao; David G Harrison
Journal:  Can J Cardiol       Date:  2020-01-24       Impact factor: 5.223

4.  Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy.

Authors:  Jie Huang; Yang Liu; Jia-Xin Chen; Xin-Ya Lu; Wen-Jia Zhu; Le Qin; Zi-Xuan Xun; Qiu-Yi Zheng; Er-Min Li; Ning Sun; Chen Xu; Hai-Yan Chen
Journal:  Acta Pharmacol Sin       Date:  2021-03-30       Impact factor: 7.169

Review 5.  O-Glycosylation with O-linked β-N-acetylglucosamine increases vascular contraction: Possible modulatory role on Interleukin-10 signaling pathway.

Authors:  Jéssica S G Miguez; Vanessa Dela Justina; Alecsander F M Bressan; Patrícia G F Marchi; Adenilda C Honorio-França; Fernando S Carneiro; R Clinton Webb; Rita C Tostes; Fernanda R Giachini; Victor V Lima
Journal:  Life Sci       Date:  2018-07-31       Impact factor: 5.037

6.  Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart.

Authors:  Scott P Levick; David B Murray; Joseph S Janicki; Gregory L Brower
Journal:  Hypertension       Date:  2010-01-04       Impact factor: 10.190

7.  Association Between Interleukin-18 Level and Left Ventricular Mass Index in Hypertensive Patients.

Authors:  Süleyman ÖZzbïçer; Zekiye Melek Uluçam
Journal:  Korean Circ J       Date:  2017-03-13       Impact factor: 3.243

Review 8.  Biomarkers of Inflammation in Left Ventricular Diastolic Dysfunction.

Authors:  Mihaela Mocan; Larisa Diana Mocan Hognogi; Florin Petru Anton; Roxana Mihaela Chiorescu; Cerasela Mihaela Goidescu; Mirela Anca Stoia; Anca Daniela Farcas
Journal:  Dis Markers       Date:  2019-06-02       Impact factor: 3.434

9.  Effect of acupuncture on essential hypertension: A protocol for systematic review and meta-analysis.

Authors:  Jing Yu; Yi Wei; Yang Jing; Yongli Gao
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.